

Quantification of cells expressing mesenchymal stem cell markers in healthy and osteoarthritic synovial membranes

Tamara Hermida-Gómez, Isaac Fuentes-Boquete, Maria José Gimeno-Longas, Emma Muiños-López, Silvia Díaz-Prado, Francisco Javier de Toro, and Francisco Javier Blanco

Abstract

Objective. To quantify cells expressing mesenchymal stem cell (MSC) markers in synovial membranes from human osteoarthritic (OA) and healthy joints.

Methods. Synovial membranes from OA and healthy joints were digested with collagenase and the isolated cells were cultured. Synovial membrane-derived cells were phenotypically characterized for differentiation experiments using flow cytometry to detect the expression of mesenchymal markers (CD29, CD44, CD73, CD90, CD105, CD117, CD166, and STRO-1) and hematopoietic markers (CD34 and CD45). Chondrogenesis was assessed by staining for proteoglycans and collagen type II, adipogenesis by using a stain for lipids, and osteogenesis by detecting calcium deposits. Coexpression of CD44, CD73, CD90, and CD105 was determined using immunofluorescence.

Results. Cells expressing MSC markers were diffusely distributed in OA synovial membranes; in healthy synovial membrane these cells were localized in the subintimal zone. More numerous MSC markers in OA synovial membranes were observed in cells also expressing the CD90 antigen. FACS analysis showed that more than 90% of OA synovial membrane-derived cells were positive for CD44, CD73, and CD90, and negative for CD34 and CD45. OA synovial membrane-derived cells were also positive for CD29 (85.23%), CD117 (72.35%), CD105 (45.5%), and STRO-1 (49.46%). Micropellet analyses showed that the culture of cells with transforming growth factor- β 3 stimulated proteoglycan and collagen type II synthesis.

Conclusion. Synovial membranes from patients with OA contain more cells positive for CD44, CD90, and CD105 antigens than those from joints with undamaged cartilage.

Key Indexing Terms:

Mesenchymal stem cell; Cartilage osteoarthritis; Synovium

The pathogenesis of osteoarthritis (OA) is characterized by the progressive destruction of articular cartilage. The capacity of articular cartilage for repair is limited, and the spontaneous repair that does occur is produced by the synthesis of a fibrocartilage¹. Mesenchymal stem cells (MSC) have been identified in human articular cartilage from patients with OA. These progenitor cells have been implicated in the process of cartilage repair; however, their role in the pathogenesis of OA is incompletely understood^{2,3}.

MSC are multipotent cells having the capacity to differentiate into various cell lineages, some of which generate bone, cartilage, and adipose tissue⁴. Bone marrow MSC are characterized by the presence of surface markers (e.g., CD44, CD54, CD71, CD90, CD166) or their absence (e.g., CD14, CD34, CD45 MSC)⁵. However, MSC show phenotypic and functional differences depending upon their tissue of origin. For example, MSC from bone marrow and synovial membrane have been differentiated by their gene expression profiles⁶.

Osteoarthritic synovial membranes may be normal in appearance, showing no intimal hyperplasia or cellular infiltrate, or fibrotic, with increased vasculature and incorporation of fragments of cartilage and bone from the joint surface. Cells expressing MSC markers have been found in the intimal lining and subintimal layers of synovial tissue, scattered in areas with small blood vessels and lymphoid aggregates^{7,8}. Data from comparative studies of MSC derived from various mesenchymal tissues suggest that the MSC from synovial membranes have superior capacity for chondrogenesis^{9,10}.

MSC from joint effusions and bone marrow aspirates show similar phenotypes and have a comparable capacity to form colony-forming units, or fibroblasts^{11,12,13,14}. MSC in synovial fluid were more numerous in patients with OA than in healthy individuals¹⁵; however, detailed quantification studies of cells expressing MSC markers in synovial membranes have not been performed.

When cartilage is damaged, repair mechanisms are initiated. Frequently a lesion of cartilage is covered by a fibrous tissue-like membrane with few layers of cells. This tissue could be produced to repair a cartilage lesion but it is not biomechanically competent, and in the end a cartilage degradation process may happen. We have called this “spontaneous repair tissue,” where spontaneous repair may be assumed to occur. There are no studies that have focused on the quantification and distribution of the MSC markers from this tissue.

The aims of our study were to identify cells with chondrogenic capacity in the synovial membranes of patients with OA; to analyze quantitative differences in the number of synovial membrane cells expressing the MSC markers CD44, CD73, CD90, and CD105, from healthy and OA human joints; and to determine if cells expressing these MSC markers are present in spontaneous cartilage repair. In patients with OA we found twice as many cells expressing the MSC markers as in normal synovia. In addition, cells positive for CD44 and CD90 antigens were found in tissue undergoing “spontaneous repair,” whereas CD105 antigen was not expressed by cells located in “spontaneous repair” tissue.

MATERIALS AND METHODS

Harvest of synovial and spontaneous repair tissues. Immediately after hip joint surgery for prosthetic replacement, synovial samples were obtained aseptically from 20 patients with OA (mean age 65 yrs, range 50–70 yrs). Synovia from normal joints was obtained from 6 organ donors with histological normal tissue (mean age 47 yrs, range 35–55 yrs). For histological analysis hematoxylin-eosin staining was performed on each sample to determine whether it was normal. Synovial membranes were placed in sterile Eagle’s minimum essential medium (EMEM; Cambrex, Walkersville, MD, USA) supplemented with 10,000 IU/ml penicillin and 10,000 µg/ml streptomycin for transport to the laboratory. Synovial membrane samples from each patient were also immersed in isopentane/liquid N₂ and held at –80°C until processed for immunostaining.

Spontaneous repair tissue from articular cartilage was obtained from human femoral heads, from the fibrous areas of OA cartilage. Samples were frozen in mounting medium for further immunohistochemical analysis.

This study was approved by the local ethics committee; informed consent was obtained from each patient.

Immunofluorescence of synovial membranes and cartilage. Frozen sections 4 µm thick were placed on Superfrost Plus slides (Menzel-Glaser, Braunschweig, Germany) and fixed in acetone at 4°C for 10 min. Monoclonal antibodies were used for immunofluorescence detection of CD44, CD73, CD90, and CD105 (Table 1 lists antibodies and their clones and sources).

For CD44/CD90 and CD44/CD73 double-immunofluorescence assessment, sections were first exposed to mouse anti-human CD44 antibody (1:100). After incubation with rabbit anti-mouse immunoglobulins-FITC (1:10), the sections were exposed to mouse anti-human CD90 antibody (1:400) or mouse anti-human CD73-RPE antibody (1:1000). The CD44/CD90 immunofluorescence samples were then incubated with goat anti-mouse immunoglobulins-RPE (1:20). Immunofluorescence was green for CD44 and CD90 and red for CD44 and CD73.

For CD44/CD105 or CD90/CD105 or CD73/CD105 double-immunofluorescence, the sections were first exposed to monoclonal anti-human CD105-FITC antibody (1:10). After incubation with mouse anti-human CD44 antibody (1:100) or mouse anti-human CD90 antibody (1:400) or mouse anti-human CD73-RPE antibody (1:1000), the CD44/CD105 and CD90/CD105 sections were incubated with goat anti-mouse immunoglobulins-RPE (1:20). CD105 immunofluorescence was green, while CD44 or CD90 or CD73 immunofluorescence was red.

To determine CD73/CD90 double-immunofluorescence, the sections were exposed to monoclonal mouse anti-human CD90 antibody (1:400). After incubation with rabbit anti-mouse immunoglobulins-FITC (1:10), sections were exposed to mouse anti-human CD73-RPE antibody (1:1000).

All incubations were accomplished within 30 min at room temperature in darkness. Between each incubation sections were washed in phosphate buffered saline. Negative-staining controls were obtained by omitting the primary antibody and incubating with the secondary antibodies conjugated with FITC or RPE. Nuclei were counterstained with DAPI (4',6-diamidino-2-phenylindole) at 100 ng/ml for 20 min. The sections were mounted in glycerol (Dako, Carpinteria, CA, USA).

Immunoperoxidase staining of paraffin-embedded tissue sections. Synovial membranes and micropellets were fixed in 4% paraformaldehyde and embedded in paraffin. Sections 4 μm thick were placed on Superfrost Plus slides and incubated with an anti-CD90 antigen monoclonal antibody (Table 1). The peroxidase/DAB ChemMate™ Dako EnVision™ detection kit was employed to detect the antigen-antibody reaction. Negative-staining controls were created by omission of the primary or secondary antibodies.

Table 1. Antibodies used in this study.

Specificity	Clone	Antigen Retrieval	Source
Flow cytometry			
RPE-CD29	MAR4		BD Pharmingen
RPE-CD34	581		BD Pharmingen
FITC-CD44	IM7		BD Pharmingen
FITC-CD45	HI30		BD Pharmingen
PE-CD73	AD2		BD Pharmingen
PE-Cy5-CD90	5E10		BD Pharmingen
FITC-CD105	8E11		Chemicon
APC-CD117	YB5.B8		BD Pharmingen
RPE-CD166	3A6		BD Pharmingen
STRO-1	NS1-Ag4-1		Developmental Studies Hybridoma Bank
Immunohistochemistry			
Collagen type I	COL-1	Hyaluronidase	Abcam
Collagen type II	COL-2	Hyaluronidase	Abcam
Chondroitin 4 sulfate	2B6	Chondroitinase	ICN Biomedicals, Inc.
Integrin subunit β 1	4B7R		Abcam
Keratan sulfate	5D4	Chondroitinase	Seikagaku America
CD90	5E10		BD Pharmingen
Immunofluorescence			
Mouse anti-human CD44 HCAM	DF1485		Santa Cruz Biotechnology
Mouse anti-human CD90 (Thy-1)			BD Pharmingen
Mouse anti-human CD105-FITC	MCA1557F		Serotec
Rabbit anti-mouse immunoglobulin-FITC			Dako
Goat anti-mouse immunoglobulin-RPE			Dako

RPE: R-phycoerythrin; FITC: fluorescein; PE: phycoerythrin; APC: allophycocyanin; HCAM: homing cell adhesion molecule

Morphometric analysis. For each sample, 5 consecutive sections were analyzed using an Olympus BX61 microscope connected to an Olympus DP70 digital camera. Images were acquired from 4 fields for each section. Cells with DAPI nuclear staining and cells with single CD44, CD73, CD90, or CD105 or double CD44/CD73, CD44/CD90, CD44/105, CD73/CD90, CD73/CD105, or CD90/105 immunostaining were independently quantified. At least 2×10^3 cells were counted for each staining experiment and percentages of stained cells were calculated.

The results represent comparisons of 2 antigen pairs. In each sample, the percentage of cells positive for a marker was calculated by dividing the number of cells expressing the marker by the number of cells stained with DAPI. The percentage of cells expressing 2 markers simultaneously was calculated by dividing the number of cells double-positive for the 2 markers by the number of cells stained with DAPI. The percentage of the isolated expression of each antigen was calculated by subtracting the percentage of cells positive for this marker from the percentage of cells expressing both markers simultaneously. The total percentage of positive cells was calculated as the sum of the percentages of the isolated expression of each antigen and its coexpression. The results are expressed as mean \pm standard deviation.

Cell culture. Synovial membranes were dissected from associated tissues under sterile conditions, digested with 0.2% solution of collagenase type I (Gibco BRL, Life Technologies, Barcelona, Spain) in EMEM for 2 h at 37°C, centrifuged, and filtered through a 40- μm filter. Synovial membrane-derived cells (10,000 cells/cm²) were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM; Cambrex) supplemented with 20% fetal bovine serum (FBS) and 10,000 IU/ml penicillin and 10,000

µg/ml streptomycin (both from Gibco BRL) in a humidified 5% CO₂ atmosphere at 37°C. The culture medium was replaced twice weekly.

When the synovial membrane-derived cells became confluent, they were released using trypsin-EDTA (Sigma-Aldrich, St. Louis, MO, USA). To reduce contamination by fibroblasts, the resultant cell suspension was subjected to a preplating technique¹⁶. The basis for this technique is that synoviocytes require more time to attach to the culture dish than fibroblasts. Therefore, cells that had not adhered within 20 min were resuspended in fresh medium and reseeded. All experiments were performed with cells from the second passage.

Cell characterization by flow cytometry. Synovial membrane-derived cells were harvested, centrifuged, washed, and counted prior to flow cytometry. Cell phenotype characterization was achieved using the formaldehydesaponin method. The 10 antibodies listed in Table 1 were used for these experiments. Optimal amounts of mouse anti-human monoclonal antibodies were determined and added to each tube for 1 h at 4°C. A control tube for each of the chromogens received equivalent amounts of isotype standards. Goat anti-mouse IgG FITC-conjugate (Southern Biotechnology, Birmingham, AL, USA) was used as a secondary antibody when necessary. A minimum of 10,000 cell-events per assay were analyzed on a FACsCalibur flow cytometer (Becton Dickinson, Madrid, Spain). Statistics were calculated by Mann-Whitney U test. Results are expressed as percent- age positive (mean ± SD). Statistical significance is accepted at $p < 0.05$.

Differentiation studies. 1. Chondrogenesis. We used a modification of the micropellet assay of Johnstone, et al¹⁷. Briefly, synovial membrane-derived cells from the second passage were counted and tested for viability using the Trypan blue dye exclusion assay. To obtain micromass cultures, 2.5×10^5 synovial membrane-derived cells were pelleted at 200 g for 5 min. The pelleted micromass was then cultured 3 weeks in chondrogenic differentiation medium supplemented with recombinant human transforming growth factor-β3 (rHuTGF-β3) at 33 ng/ml (Prospecany Technogene Ltd., Rehovot, Israel). The medium was changed every 3 or 4 days. Molecules characteristic of hyaline cartilage, such as proteoglycans and collagen type II, were detected by Alcian blue staining for proteoglycans or by immuno-histochemical techniques.

2. Adipogenesis. Synovial membrane-derived cells were seeded (2×10^5 cells/8.6 cm²) and cultured in a one-well chamber slide in growth medium (DMEM supplemented with 20% FBS) until confluent. Adipogenesis was induced by culturing for 3 weeks using adipogenic differentiation medium (Cambrex). After fixation in 4% paraformaldehyde, the presence of adipocytes in the cultures was determined using oil red O stain to visualize cytoplasmic lipid droplets.

3. Osteogenesis. Synovial membrane-derived cells were seeded (5×10^4 cells/8.6 cm²) in growth medium in a one-well chamber slide and allowed to adhere for 24 h. Osteogenesis was induced by culturing for 3 weeks using osteogenic differentiation medium (Cambrex). After fixation in 4% paraformaldehyde, the presence of calcium deposits was assessed using alizarin red stain according to the standard protocol.

Statistical analysis. All statistical analyses were performed using SPSS 16.0 software for Windows; p values < 0.05 were considered statistically significant.

RESULTS

Distribution and quantification of cells expressing MSC markers in synovial membranes. In this study, healthy and OA synovial membrane samples were analyzed for CD44, CD73, CD90, and CD105 antigens using double-immunofluorescence on frozen tissue and 2 antigens were analyzed simultaneously.

The location of the CD44, CD90, and CD105 antigens in healthy and OA synovial membranes differed markedly (Figures 1 and 2). In healthy specimens, cells expressing these markers were located in the intimal lining. In OA specimens the distribution of these antigens was more diffuse and they were located deeper than the subintimal layer in normal synovium, around veins in the perivascular matrix.




Figure 1. Cells expressing CD44, CD90, and CD105 antigens in synovial membranes shown by immunofluorescence. A, B: H&E staining of healthy (A) and osteoarthritic (B) synovial membranes. C-H: Monoclonal antibodies against CD44, CD90, and CD105 antigens were used to analyze simultaneous expression of 2 antigens in healthy and OA synovial membranes. Immunofluorescence detection of each antigen was achieved using frozen sections of synovial membranes. CD44 (green) and CD90 (red) double-immunofluorescence of healthy (C) and OA (D) synovial membranes; CD44 (red) and CD105 (green) double-immunofluorescence of healthy (E) and OA (F) synovial membranes; CD90 (red) and CD105 (green) double-immunofluorescence of healthy (G) and OA (H) synovial membranes. Bars A and B = ~100 μ m; bars C-H = ~50 μ m.




Figure 2. Cells coexpressing CD44/CD73, CD73/CD90, and CD73/CD105 antigens in synovial membranes shown by immunofluorescence. A, B: H&E staining of healthy (A) and osteoarthritic (B) synovial membranes. C-H: Monoclonal antibodies against CD44, CD73, CD90, and CD105 antigens were used to analyze simultaneous expression of CD44/CD73, CD73/CD90, and CD73/CD105 antigens in healthy and OA synovial membranes. Immunofluorescence detection of each antigen was achieved using frozen sections of synovial membranes. CD44 (green) and CD73 (red) double-immunofluorescence of healthy (C) and OA (D) synovial membranes; CD73 (red) and CD105 (green) double-immunofluorescence of healthy (E) and OA (F) synovial membranes; CD90 (red) and CD105 (green) double-immunofluorescence of healthy (G) and OA (H) synovial membranes. Bars A and B = ~100 μ m; bars C-H = ~50 μ m.

Quantification studies of healthy and OA synovial membranes showed that they expressed the antigens CD44, CD73, CD90, and CD105 differently (Figure 3A). In healthy synovial membranes only a small percentage of cells stained positively for the MSC markers CD44, CD90, and CD105 (CD44: $1.2\% \pm 0.6\%$; CD90: $2.1\% \pm 1.8\%$; and CD105: $1.4\% \pm 0.6\%$). In OA synovial membranes, these percentages were increased (CD44: $3.0\% \pm 1.7\%$; CD90: $7.7\% \pm 4.0\%$; and CD105: $2.3\% \pm 1.2\%$). The expressions of CD44 and CD90 were both significantly ($p < 0.05$) higher in OA than in healthy synovial membranes. Conversely, a high percentage of cells expressed the CD73 antigen in healthy synovial membrane ($8.5\% \pm 3.2\%$), whereas this expression was reduced substantially in OA synovial membrane ($1.8\% \pm 1.8\%$).




Figure 3. A. Expression of CD44, CD73, CD90, and CD105 antigen in synovial membranes. Graph represents the quantitative analysis of cells showing expression for each marker in healthy and OA synovial membranes. Results are expressed as mean \pm SD. * $p < 0.05$. B. Coexpression of 2 antigens in synovial membranes. Graph represents simultaneous expression of 2 antigens (CD44/CD90, CD44/CD105, CD90/CD105, CD44/CD73, CD90/CD73, and CD105/CD73) in healthy and OA synovial membranes. Results are mean \pm SD. * $p < 0.05$

Analysis of the simultaneous expression of 2 antigens also showed a higher level in OA than in healthy synovial membranes when the analyzed antigens were CD44, CD90, and CD105 (Figure 3B). Coexpression of CD44 and CD90 antigens in healthy synovial membranes was observed in $0.4\% \pm 0.3\%$ of the cells, while in OA synovia $1.6\% \pm 0.6\%$ of the cells stained for both antigens. Notably, coexpression of CD44 and CD105 antigens in healthy and OA synovial membrane ($1.3\% \pm 0.4\%$ vs $2.7\% \pm 0.4\%$, respectively) was found to be higher than the coexpression of CD44 with CD90 and CD90 with CD105. Coexpression of CD90 and CD105 antigens in healthy synovial membranes occurred in $0.5\% \pm 0.5\%$ of the cells, while $1.9\% \pm 1.5\%$ of the cells in OA synovia stained simultaneously for these antigens. In both healthy and OA synovial membrane there were low percentages of coexpression of CD73 antigen with antigens CD44, CD90, and CD105. However, this coexpression was always slightly higher in normal synovium than in OA synovium (CD44/CD73: $0.5\% \pm 0.5\%$ vs $0.2\% \pm 0.1\%$; CD73/CD90: $0.3\% \pm 0.2\%$ vs $0.0\% \pm 0.0\%$; and CD73/CD105: $0.5\% \pm 0.2\%$ vs $0.3\% \pm 0.2\%$).

The association of expression of CD44, CD73, CD90, and CD105 antigens showed differences between these markers and between healthy and OA synovial membranes. Only $13.4\% \pm 12.5\%$ and $1.9\% \pm 1.5\%$ of CD44-positive cells were also positive for antigen CD73 in healthy and OA synovium, respectively. The level of coexpression of the CD44 antigen with the CD90 antigen (Figure 4A) was moderate in healthy synovial membranes, where $44.0\% \pm 37.6\%$ of CD44-positive cells were also positive for the CD90 antigen, while this level doubled in OA synovia ($84.2\% \pm 11.6\%$ of CD44-positive cells were positive for CD90 antigen). In contrast, the expression of CD44 antigen showed a high level of association with the expression of the CD105 antigen in both healthy and OA synovial membranes (Figure 4A). Roughly $72.1\% \pm 12.3\%$ of the CD44-positive cells in healthy samples and $67.2\% \pm 6.5\%$ in OA synovial membranes were also positive for the CD105 antigen.




Figure 4. Association of the expression of CD44, CD73, CD90, and CD105 antigens in synovial membranes. Each column represents the percentage of positive cells for one antigen that are also positive for another antigen (black area in each graph) in healthy and OA synovial membranes. A. Percentage of CD44-positive cells expressing CD73 or CD90 or CD105. B. Percentage of CD90-positive cells expressing CD44 or CD73 or CD105. C. Percentage of CD105-positive cells expressing CD44 or CD73 or CD90. D. Percentage of CD73-positive cells expressing CD44 or CD90 or CD105.

The expression of the CD90 antigen had a low level of association with the expression of CD44 or CD73 or CD105 in both healthy and OA synovial membranes (Figure 4B). Nearly 25% of CD90-positive cells were also positive for the CD44 antigen or the CD105 antigen in both healthy and OA synovial membranes, whereas only $4.8\% \pm 4.7\%$ of CD90-positive cells were positive for the CD73 antigen in healthy synovium (coexpression of the CD90 and CD73 antigens was not observed in OA synovium).

The expression of the CD105 antigen showed a high level of association with the expression of CD44 in both healthy and OA synovial membranes (Figure 4C); in healthy samples $87.1\% \pm 8.8\%$ and in OA synovia $89.9\% \pm 8.4\%$ of CD105-positive cells were also positive for the CD44 antigen. On the other hand, expression of the CD105 antigen was more closely associated with the expression of CD90 in OA than in healthy synovial membranes (Figure 4C); $33.2\% \pm 19.8\%$ of the CD105-positive cells in healthy synovia were also positive for the CD90 antigen, while in OA synovia $68.1\% \pm 23.9\%$ of CD105-positive cells were also positive for CD90. Expression of the CD105 antigen showed a low level of association with expression of the CD73 antigen ($9.9\% \pm 7.5\%$ in healthy samples and $10.2\% \pm 7.9\%$ in OA synovial membrane).

Expression of the CD73 antigen showed in general a low level of association with the expression of CD44, CD90, and CD105 (Figure 4D) in both healthy and OA synovium (with CD44: $7.7\% \pm 7.6\%$ vs $42.0\% \pm 27.0\%$; with CD90: $4.9\% \pm 3.6\%$ vs $0.0\% \pm 0.0\%$; with CD105: $4.4\% \pm 3.6\%$ vs $12.8\% \pm$

12.8%). Only a moderate association was observed with the expression of the CD44 antigen in OA synovium, where only $0.2\% \pm 0.1\%$ of the cells coexpressed CD44/CD73 antigens.

In summary, synovial membranes from OA patients contain higher percentages of cells positive for CD44, CD90, and CD105 antigens than those from joints without cartilage damage. This increased expression in OA synovial membranes was observed in greater measure to the CD90 antigen. Conversely, the percentage of cells expressing the CD73 antigen was higher in healthy synovial membrane than in OA synovial membrane. However, only CD44 and CD105 antigens showed high levels of coexpression.

Cell-surface marker phenotype. FACS analysis demonstrated that cells derived from OA synovia show a cell-surface receptor pattern similar to that reported for bone marrow MSC (Figure 5). OA synovial membrane-derived cells were negative for CD34 and CD45 antigens. Nearly 95% of OA synovial membrane cells were positive for CD44, CD73, and CD90; and 45% of these cells stained for CD105 anti-gen. Cells isolated from OA synovia were also positive for CD29 ($85.2\% \pm 10.5\%$), CD117 ($72.35\% \pm 15.17\%$), STRO-1 ($49.46\% \pm 25.58\%$), CD105 ($45.5\% \pm 8.29\%$), and CD166 ($32.29\% \pm 16.69\%$) (Table 2).




Figure 5. Phenotype of cells isolated from synovial membranes of patients with OA. Antibodies listed in Table 1 were used for this procedure. Figure shows representative histograms of multipotential mesenchymal stem cells obtained from FACS analysis. Black line signifies the specific antibody; grey line represents the isotype control.

Table 2. Percentage of phenotype-positive synovial membrane cells at the second passage (n = 20). Data are shown as mean \pm SD.

CD	Specificity	Percentage of Positive Cells
CD29	Alpha-1 integrin	85.2 ± 10.5
CD44	H-CAM	99.1 ± 1.4
CD73	Ecto-5-nucleotidase	95.1 ± 23.7
CD90	Thy-1	98.2 ± 14.6
CD105	SH-2, Engoglin	45.5 ± 8.3
CD117	c-Kit, SCFR	72.3 ± 15.2
CD166	ALCAM	32.3 ± 16.7
STRO-1	Stromal antigen 1	49.5 ± 25.6

Multilineage differentiation potential of synovial membrane-derived cells. To determine whether the cells from OA synovial membranes were multipotential, we cultured the cells in chondrogenic, adipogenic, or osteogenic differentiation media using established protocols⁹.

Chondrogenesis was observed in all cell preparations analyzed (Figure 6A, 6B). Micromass cultures were tested for the presence of markers characteristic of hyaline cartilage using Alcian blue staining for proteoglycans and immunodetection of collagen type II. Proteoglycans and collagen type II were located throughout the newly formed matrix, with the highest staining intensity in the core of the micropellets.




Figure 6. Chondrogenic, adipogenic, and osteogenic capacities of synovial membrane cells from patients with OA. Chondrogenesis was assessed by incubation of micropellet cultures in chondrogenic differentiation medium and TGF- β 3. The resulting micromass was stained for proteoglycans with Alcian blue (a). Immunodetection of collagen type II is shown (b). Presence of adipocytes was assessed by detection of lipid droplets by oil red O staining (c); presence of calcium deposits was determined by staining with alizarin red (d). Original magnification $\times 100$ for all photographs

Synovial membrane-derived cells cultured in adipogenic medium developed lipid droplets, an indicator of adipogenic differentiation (Figure 6C). The osteogenic potential of synovial membrane-derived cells cultured in osteogenic media was demonstrated using alizarin red stain to show calcification (Figure 6D).

Quantification of cells expressing CD44, CD90, and CD105 antigens in “spontaneous repair” tissue. Analysis of localized spontaneous repair tissues covering the OA-damaged cartilage showed cells that expressed the characteristic antigens of MSC (Figures 7A, 7B), such as CD44 ($10.2\% \pm 1.5\%$) and CD90 ($12.3\% \pm 2.1\%$). The expression of CD44 was only slightly associated with the expression of CD90 antigen; only $0.71\% \pm 0.5\%$ of cells coexpressed both anti- gens. In spontaneous repair tissue 5.6% of CD44-positive cells were also positive for CD90, and 6.7% of CD90-positive cells were also positive for CD44 antigen. Interestingly, the CD105 antigen was not present in spontaneous repair tissue.

DISCUSSION

This study confirms for the first time that OA synovia contain more cells expressing MSC markers than do synovial membranes from healthy joints. In addition, we demonstrated that synovial membranes from patients with OA contain MSC with chondrogenic capacity and that “spontaneous repair” tissue from OA cartilage contains cells expressing MSC markers.

The presence of MSC in synovial membranes was recently reported^{7,8}. These investigators defined the cells as mesenchymal because of their phenotypic profile and potential for differentiation; these cells were also shown to have ultrastructural and morphologic features similar to B synoviocytes¹⁸. Although there are no specific markers to identify MSC, a number of monoclonal antibodies for phenotypically characterizing these tissue-derived stem cells have been developed⁵. The general consensus is that MSC should be negative for the hematopoietic markers CD34 and CD45, and positive for CD44, CD73, CD90, and CD105⁴.

The culture conditions used to isolate MSC from the synovium are similar to those used to obtain fibroblastic synoviocytes and are based, in part, on the fact that synoviocytes require more time to attach to the culture dish than MSC. This suggests that only a subset of cells in the synovium-derived cell population is constituted of stem cells. Because no specific marker for MSC is presently available, MSC characterization is currently based on their functional properties. To improve the number of MSC isolated from synovial membranes, we used a preplating technique that minimizes the number of contaminating fibroblasts in the culture¹⁶. We used surface markers found on cells with multipotential properties to phenotypically characterize MSC. Our cell population was phenotypically characterized by simultaneous positive staining for CD44, CD73, and CD90; nearly 95% of all MSC expressed these antigens, which have been identified as markers for undifferentiated bone marrow MSC and synovium-derived adherent cells^{6,12,13,19}.

In addition, we demonstrated that, under appropriate conditions, synovial membrane-derived cells can differentiate into chondrocytes, adipocytes, or osteoblasts. These findings indicate that synovia from OA patients have a cell population with multilineage properties possessing phenotypic markers similar to those observed for bone marrow MSC. These results confirm that the synovial membrane-derived cells observed in our study could be legitimately designated as MSC.

A previous quantitative study of the MSC population in OA synovia has been performed; however, the study employed flow cytometry and did not compare OA with normal synovia⁸. We carried out for the first time a comparative semiquantitative study of cells expressing MSC markers using OA and normal synovial samples. We were also able to elucidate the tissue distribution of MSC in synovial membranes and show that OA synovia contain a higher number of cells expressing MSC markers than normal synovia.

The presence of cells expressing MSC markers in the synovial tissues of patients with OA raises the question whether these cells appear in the joint as a result of inflammatory processes or whether they are already present prior to onset of the disease. It has been suggested that mesenchymal cells are among the earliest cells to arrive in the prearthritic joint¹⁵. In an effort to resolve this question, we were able to demonstrate that the synovial tissue of healthy donors contains MSC markers before any active articular inflammatory process occurs. We also note that during degenerative inflammatory processes a number of our OA cases presented with typical features of an inflammatory condition with chronic synovitis, including intimal cell hyperplasia and infiltration of lymphocytes, plasma cells, and monocyte/macrophage cells. The inflammatory cells found in synovial membranes are derived from bone marrow and transported through the vascular system and peripheral blood. MSC may also migrate to OA synovial membranes in the same way. We demonstrated that CD44/CD90 is located in the subintimal zone and around blood vessels in the synovium. Other investigators suggest that canals between the bone marrow and synovium allow migration of bone marrow MSC into the synovium of inflamed joints². Because activated osteoclasts were found in close proximity to enlarged canals, the mechanism of formation of bone canals is at least partly osteoclast-mediated².

When a tissue is damaged, repair mechanisms are initiated that involve stem cells and inflammatory cells already in the compromised tissue or migrating to it through the vascular system. Because articular cartilage is avascular, it must either self-repair or rely on neighboring tissues for repair. It has been reported that human articular cartilage tissue has MSC that may participate in the repair of cartilage lesions². A further factor in the repair process involves the synovial membrane as a potential source of nutrients and other factors that modulate cartilage repair^{13,20}. It is possible that the MSC having chondrogenic potential that are present in the synovial membrane can migrate to the damaged cartilage to participate in the active process of cartilage regeneration and repair. In support of this possibility, MSC have been found in the synovial fluid of patients with OA¹⁵. We analyzed the tissue covering damaged

cartilage in patients with OA (we have called this “spontaneous repair tissue”), where spontaneous tissue repair may be assumed to occur, and found cells expressing MSC markers (CD44 and CD90) that show a phenotype similar to MSC identified in OA synovial membranes. Although cells expressing MSC markers are located in spontaneous repair tissue of patients with OA, the capacity of these cells to repair cartilage may be limited by the cartilage degradation progress. The finding that the CD105 antigen is not expressed by cells located in repair tissue could suggest that these cells are necessary for repair processes to be effective in OA cartilage.

In summary, cells with the characteristic phenotype of MSC were isolated from OA synovial membranes. These cells have the capacity to differentiate into chondrocytes in vitro. Synovial membranes from patients with OA contain more cells expressing MSC markers than do those from joints with no cartilage damage. Spontaneous cartilage repair tissue contains cells positive for CD44 and CD90, but the CD105 antigen was absent.

ACKNOWLEDGMENT

The authors express appreciation to all members of the Department of Orthopedics and the Tissue Bank of the Complejo Hospitalario Universitario A Coruña for providing synovial samples. We thank Pilar Cal for expert secretarial support. We also thank Purificación Filgueira and M. José Sánchez for excellent technical assistance.

REFERENCES

1. Brandt KD, Mazzuca SA. Experience with a placebo-controlled randomized clinical trial of a disease-modifying drug for osteoarthritis: the doxycycline trial. *Rheum Dis Clin North Am* 2006;32:217-34.
2. Alsalameh S, Amin R, Gemba T, Lotz M. Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. *Arthritis Rheum* 2004;50:1522-32.
3. Douthwaite GP, Bishop JC, Redman SN, Khan IM, Rooney P, Evans DJ, et al. The surface of articular cartilage contains a progenitor cell population. *J Cell Sci* 2004;117:889-97.
4. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315-7.
5. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy* 2005;7:393-5.
6. Djouad F, Bony C, Häupl T, Uze G, Lahlou N, Louis-Pence P, et al. Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal cells. *Arthritis Res Ther* 2005;7:R1304-15.
7. De Bari C, Dell’Acio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum* 2001;44:1928-42.
8. Fickert S, Fiedler J, Brenner RE. Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. *Osteoarthritis Cartilage* 2003;11:790-800.
9. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. *Arthritis Rheum* 2005;52:2521-9.
10. Shirasawa S, Sekiya I, Sakaguchi Y, Yagishita K, Ichinose S, Muneta T. In vitro chondrogenesis of human synovium-derived mesenchymal stem cells: Optimal condition and comparison with bone marrow-derived cells. *J Cell Biochem* 2006;97:84-97.
11. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU, et al. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res* 1998;238:265-72.
12. Lee RH, Kim B, Choi I, Kim H, Choi HS, Suh K, et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. *Cell Physiol Biochem* 2004;14:311-24.
13. Majumdar MK, Banks V, Peluso DP, Morris EA. Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. *J Cell Physiol* 2000;185:98-106.
14. Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. *Arthritis Rheum* 2002;46:3349-60.
15. Jones EA, English A, Henshaw K, Kinsey SE, Markham AF, Emery P, et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. *Arthritis Rheum* 2004;50:817-27.
16. Richler C, Yaffe D. The in vitro cultivation and differentiation capacities of myogenic cell lines. *Dev Biol* 1970;23:1-22.
17. Fuentes-Boquete I, López-Armada MJ, Maneiro E, Fernández-Sueiro JL, Caramés B, Galdo F, et al. Pig chondrocyte xenografts for human chondral defect repair: an in vitro model. *Wound Repair Regen* 2004;12:444-52.

18. Vandenabeele F, De Bari C, Moreels M, Lambrichts I, Dell'Accio F, Lippens PL, et al. Morphological and immunocytochemical characterization of cultured fibroblast-like cells derived from adult human synovial membrane. *Arch Histol Cytol* 2003;66:145-53.
19. Barry F, Boynton R, Murphy M, Haynesworth S, Zaia J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. *Biochem Biophys Res Commun* 2001;289:519-24. Erratum in: *Biochem Biophys Res Commun* 2002;290:1609.
20. Hunziker EB, Rosenberg LC. Repair of partial-thickness defects in articular cartilage: cell recruitment from the synovial membrane. *J Bone Joint Surg Am* 1996;78:721-33.